logo

Abbvie (ABBV)



Trade ABBV now with
  Date
  Headline
2/19/2019 8:32:18 AM AbbVie Announces NDA Accepted For Priority Review For Upadacitinib For Moderate To Severe Rheumatoid Arthritis
1/28/2019 7:12:12 AM AbbVie Announces U.S. FDA Approval Of IMBRUVICA Plus Obinutuzumab
1/25/2019 7:43:40 AM AbbVie Q4 Adjusted EPS, Excluding Specified Items, Up 28.4% To $1.90
1/3/2019 8:39:00 AM AbbVie, Tizona Announce Strategic Collaboration To Develop First-in-Class Immunotherapy For Cancer Targeting CD39
12/20/2018 8:55:04 AM AbbVie Submits NDA To FDA And MAA To EMA For Upadacitinib For Treatment Of Moderate To Severe Rheumatoid Arthritis
12/14/2018 2:15:54 AM BioArctic Outlicenses Its Alpha-synuclein Antibody Portfolio For Parkinson's Disease To AbbVie After Receiving Clearance
12/13/2018 1:06:21 PM AbbVie (ABBV) Announces $5 Bln Stock Repurchase Plan
11/30/2018 10:08:00 AM Pfizer To Pay Royalties To AbbVie For Licensing Its HUMIRA Patents; AbbVie To Make No Payments To Pfizer
11/15/2018 3:02:20 AM Mission Therapeutics, AbbVie Sign DUBs Collaboration In Alzheimer’s And Parkinson’s Disease
11/6/2018 4:45:56 PM AbbVie Announces Patent License Agreements With Momenta Over Proposed Biosimilar Adalimumab Product
11/2/2018 7:48:59 AM AbbVie Q3 GAAP EPS $1.81; Adjusted EPS $2.14
11/1/2018 11:14:19 PM BioArctic's Partner AbbVie Exercises Option To License Alpha-synuclein Antibody Portfolio For Parkinson's Disease
11/1/2018 12:08:01 AM AbbVie Receives European Commission Approval Of VENCLYXTO Plus Rituximab For Chronic Lymphocytic Leukemia